03.10.2012 • News

Monsanto Posts Q4 Loss as Corn Seeds Sales Slip

Global agribusiness group Monsanto posted a fourth-quarter loss on Wednesday, as expected, amid a seasonally sluggish sales period, and offered a conservative outlook for the new year.

For the fiscal year just ended, Monsanto said ongoing earnings growth hit 25%, excluding unusual items, but the company forecast mid-teens ongoing earnings growth for 2013.

Sales totaled $2.11 billion for the quarter ended Aug. 31, down from $2.25 billion a year before, as corn seeds and trait sales declined year to year.

Monsanto, the world's largest seed company and a developer of genetically engineered corn, soybeans, and other crops, posted a quarterly loss of 44 cents a share on an ongoing basis, excluding a restructuring charge of 2 cents a share, worse than the loss of 22 cents a share a year before but in line with analysts' expectations.

On a net basis, the company lost $229 million, or 42 cents a share, for the quarter, compared with a loss of $112 million, or 21 cents a share, a year before.

Company officials said the base business in the United States was complemented by its growing international seeds and traits performance.

Sales of corn seeds and traits dropped 12% in the fourth quarter from a year ago, and cotton sales were off 84%. Quarterly soybean sales, meanwhile, jumped 48%, and vegetable seed sales were up 26% year over year.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read